Antidepressant-like behavioral effects of IGF-I produced by enhanced serotonin transmission

European Journal of Pharmacology

Volumn 594, Issue 1-3, 2008, Pages 109-116

  Hoshaw, Brian A ^a   Hill, Tiffany I ^a   Crowley, James J ^a   Malberg, Jessica E ^b   Khawaja, Xavier ^b   Rosenzweig Lipson, Sharon ^b   Schechter, Lee E ^b   Lucki, Irwin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PFIZER INC   (United States)

Author keywords

(Rat); Animal model; Depression; Forced swim test; Neurogenesis; Neurotrophin

Indexed keywords

CITALOPRAM; DESIPRAMINE; MESSENGER RNA; PAROXETINE; SEROTONIN; SOMATOMEDIN C; TRYPTOPHAN HYDROXYLASE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN CORTEX; CELL PROLIFERATION; DEPRESSION; DRUG EFFECT; FORCED SWIMMING TEST; HIPPOCAMPUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; CELL PROLIFERATION; CITALOPRAM; DENTATE GYRUS; DESIPRAMINE; HIPPOCAMPUS; INSULIN-LIKE GROWTH FACTOR I; MALE; NERVE GROWTH FACTORS; PAROXETINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, IGF TYPE 1; RNA, MESSENGER; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SWIMMING; SYNAPTIC TRANSMISSION; TRYPTOPHAN HYDROXYLASE;

EID: 50549086770     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.07.023     Document Type: Article

References (48)

1. Aberg M.A., Aberg N.D., Hedbacker H., Oscarsson J., and Eriksson P.S. Peripheral infusion of IGF-I selectively induces neurogenesis in the adult rat hippocampus. J. Neurosci. 20 (2000) 2896-2903
2. Aberg M.A., Brywe K.G., and Isgaard J. Aspects of growth hormone and insulin-like growth factor I related to neuroprotection, regeneration, and functional plasticity in the adult brain. Scientific World Journal 6 (2006) 53-80
3. Aguado F., Rodrigo J., Cacicedo L., and Mellstrom B. Distribution of insulin-like growth factor-I receptor mRNA in rat brain. Regulation in the hypothalamo-neurohypophysial system. J. Mol. Endocrin. 11 (1993) 231-239
4. Airan R.D., Meltzer L.A., Roy M., Gong Y., Chen H., and Deisseroth K. High-speed imaging reveals neurophysiological links to behavior in an animal model of depression. Science 317 (2007) 819-823
5. Altar C.A. Neurotrophins and depression. Trends Pharmacol. Sci. 20 (1999) 59-61
6. Bondy C.A., and Lee W.H. Patterns of insulin-like growth factor and IGF receptor gene expression in the brain. Functional implications. Ann. N. Y. Acad. Sci. 692 (1993) 33-43
7. Camarero G., Leon Y., Gorospe I., De Pablo F., Alsina B., Giraldez F., and Varela-Nieto I. Insulin-like growth factor 1 is required for survival of transit-amplifying neuroblasts and differentiation of otic neurons. Dev Biol. 262 (2003) 242-253
8. Campbell S., and Macqueen G. The role of the hippocampus in the pathophysiology of major depression. J. Psychiatr. Neurosci. 29 (2004) 417-426
9. Castren E. Neurotrophic effects of antidepressant drugs. Curr. Opin. Pharmacol. 4 (2004) 58-64
10. Clemmons D.R. IGF binding proteins: regulation of cellular action. Growth Regulation 2 (1992) 80-87
11. Crown W.H., Finkelstein S., Berndt E.R., Ling D., Poret A.W., Rush A.J., and Russell J.M. The impact of treatment-resistant depression on health care utilization and costs. J. Clin. Psychiatr. 63 (2002) 963-971
12. Cryan J.F., Valentino R.J., and Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified forced swim test. Neurosci. Biobehav. Rev. 29 (2005) 547-569
13. Dechant G., and Neumann H. Neurotrophins. Adv. Exp. Biol. 513 (2002) 303-334
14. Detke M.J., Rickels M., and Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 121 (1995) 66-72
15. Duman R.S. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromol. Med. 5 (2004) 11-25
16. Duman R.S., and Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychatry 59 (2006) 1116-1127
17. Ezzat V.A., Duncan E.R., Wheatcroft S.B., and Kearney M.T. Diabetes Obes. Metab. 10 (2008) 198-211
18. Garcia L.S., Comim C.M., Valvassori S.S., Réus G.Z., Barbosa L.M., Andreazza A.C., Stertz L., Fries G.R., Gavioli E.C., Kapczinski F., and Quevedo J. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 140-144
19. Guan J., Bennet L., Gluckman P.D., and Gunn A.J. Insulin-like growth factor-1 and post-ischemic brain injury. Prog. Neurobiol. 70 (2003) 443-462
20. Harkin A., Connor T.J., Walsh M., St John N., and Kelly J.P. Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 44 (2003) 616-623
21. Hoshaw B.A., Evans J.C., Mueller B., Valentino R.J., and Lucki I. Social competition in rats: cell proliferation and behavior. Behav Brain Res. 175 (2006) 343-351
22. Hoshaw B.A., Malberg J.E., and Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res. 1037 (2005) 204-208
23. Kar S., Chabot J.G., and Quirion R. Quantitative autoradiographic localization of [125I] Insulin-like growth factor,[125I] Insulin-like growth factor II, and [125I] Insulin receptor binding sites in developing and adult brain. J. Comp. Neurol. 333 (1993) 375-395
24. Koe B.K., and Weissman A. p-Chlorophenylalanine: a specific depletor of brain serotonin. J. Pharmacol. Exp. Ther. 154 (1966) 499-516
25. Kreiss D.S., and Lucki I. Chronic administration of the 5-HT1A receptor agonist 8-OH-DPAT differentially desensitizes 5-HT1A autoreceptors of the dorsal and median raphe nuclei. Synapse 25 (1997) 107-116
26. Laron Z. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity). Pediatr. Endocrinol. Rev. 5 (2008) 766-771
27. Le Roith D., Werner H., Beitner-Johnson D., and Roberts C.T. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocrine Rev. 16 (1995) 143-163
28. Lopez-Lopez C., LeRoith D., and Torres-Aleman I. Insulin-like growth factor I is required for vessel remodeling in the adult brain. Proc. Nat. Acad. Sci. 101 (2004) 9833-9838
29. Malberg J.E., Eisch A.J., Nestler E.J., and Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 20 (2000) 9104-9110
30. Malberg J.E., Platt B., Sukoff-Rizzo S.J., Ring R.H., Lucki I., Schechter L.E., and Rosenzweig-Lipson S. Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology 32 (2007) 2360-2368
31. National-Research-Council. Guide for the Care and Use of Laboratory Animals (1996), National Academy Press, Washington, DC
32. Page M.E., Cryan J.F., Sullivan A., Dalvi A., Saucy B., Manning D.R., and Lucki I. Behavioral and neurochemical effects of 5-{4-[4-(5-cyano-3-indolyl)-butyl)-butyl]-1-piperaziny}-benzofuran-2-carboxamide(EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine1A receptor partial agonist. J. Pharmacol. Exp. Ther. 302 (2002) 1-8
33. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, North Ryde, N.S.W.
34. Redrobe J.P., Dumont Y., Fournier A., Baker G.B., and Quirion R. Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim test. Peptides 26 (2005) 1394-1400
35. Ryan P.D., and Goss P.E. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 13 (2008) 16-24
36. Saarelainen T., Hendolin P., Lucas G., Koponen E., Sairanen M., MacDonald E., Agerman K., Haapasalo A., Nawa H., Aloyz R., Ernfors P., and Castren E. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci., 23 (2003) 349-357
37. Sanger M. Neurotrophins: possible role in affective disorders. Human Psychopharmacol. 16 (2001) 61-64
38. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., Belzung C., and Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301 (2003) 805-809
39. Schechter L.E., Ring R.H., Beyer C.E., Hughes Z.A., Khawaja X., Malberg J.E., and Rosenzweig-Lipson S. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2 (2005) 590-611
40. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., and Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22 (2002) 3251-3261
41. Siuciak J.A., Lewis D.R., Wiegand S.J., and Lindsay R.M. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol. Biochem. Behav. 56 (1997) 131-137
42. Torres-Aleman I. Targeting insulin-like growth factor-1 to treat Alzheimer's disease. Expert Opin. Ther. Targets 11 (2007) 1535-1542
43. Trejo J.L., Carro E., and Torres-Aleman I. Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. J. Neurosci. 21 (2001) 1628-1634
44. Vollmayr B., Mahlstedt M.M., and Henn F.A. Neurogenesis and depression: what animal models tell us about the link. Eur. Arch. Psychiatry Clin. Neurosci. 257 (2007) 300-303
45. Warner-Schmidt J.L., and Duman R.S. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 16 (2006) 239-249
46. Wilczak N., and de Keyser J. Insulin-like growth factor system in amyotrophic lateral sclerosis. Endocrine Development 9 (2005) 160-169
47. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., and Manji H.K. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant depression. Arch. Gen. Pscyhiatry 63 (2006) 856-864
48. Zigova T., Pencea V., Wiegand S.J., and Luskin M.B. Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb. Mol. Cell. Neurosci. 11 (1998) 234-245